Sensus Healthcare

Sensus Healthcare, Inc. operates as a medical device company, which provides treatments for both oncological and non-oncological skin conditions. The firm's portfolio of treatment devices includes the SRT-100, SRT-100+, and SRT-100 Vision. Its main product superficial radiation therapy (SRT), a photon x-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating basal cell and squamous cell skin cancers, and other skin conditions, such as keloids. The company was founded by Joseph C. Sardano, Richard Golin, Kalman Fishman, and Stephen Cohen on May 7, 2010 and is headquartered in Boca Raton, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Sensus Healthcare reports solid Q4 earnings, eyes growth opportunities

Sensus Healthcare's Q4 2022 earnings call highlighted strong revenue performance, strategic growth initiatives, and a focus on expense management. The company aims to leverage opportunities in technology enhancements, market expansion, and revenue growth while addressing challenges related to net income decline and managing expenses effectively.

Sensus Healthcare adapts to inflation challenges, eyes global expansion

Sensus Healthcare navigated a challenging Q1 2023 marked by inflation impacts, focusing on product demand, cost management, and international expansion to drive future growth.
Despite financial setbacks, the company's innovative SRT system, strategic initiatives, and collaborations position it well to capitalize on opportunities in the radiation oncology market and international territories.
Addressing inflation challenges, securing purchase orders efficiently, and leveraging partnerships with hospitals and pharmaceutical companies are key focus areas for Sensus Healthcare's sustainable growth strategy.

Sensus Healthcare reports Q2 growth, eyes profitability amid market challenges

Sensus Healthcare showed improved performance in Q2 but faced challenges with declining profits and negative EBITDA.
The company's strengths lie in new software introductions, marketing expansions, and AI development for product enhancement.
Opportunities include expected profitability, market recovery signs, international expansion, and investor engagement strategies.
To address challenges, Sensus needs to navigate financial pressures, regulatory hurdles, and competitive dynamics effectively.

Sensus Healthcare reports Q3 revenue decline but eyes international expansion

Sensus Healthcare faced revenue decline in Q3 but remains confident in growth prospects, emphasizing proper business management to mitigate risks.
The company's focus on international expansion and innovative clinic management solutions presents opportunities for future revenue growth and market penetration.
Despite challenges in the industry and competitive landscape, Sensus Healthcare's financial stability and strategic initiatives position it for continued success.

Sensus Healthcare excels in Q4, eyes international expansion and innovative revenue models

Sensus Healthcare's Q4 performance reflects strong sales and financial stability, positioning the company for growth.
Innovative products and new revenue models showcase the company's commitment to market expansion and revenue diversification.
While challenges exist in market expansion and cost control, strategic opportunities in international markets and new models offer avenues for growth.

Sensus Healthcare posts stellar Q1 results, eyes global expansion

Sensus Healthcare delivered outstanding results in Q1 2024, marked by robust revenue growth, operational excellence, and financial strength.
While facing challenges in maintaining growth momentum and navigating international markets, the company's strategic strengths and opportunities position it for continued success.
With a focus on innovation, market expansion, and strategic partnerships, Sensus Healthcare is poised to capitalize on its current momentum and drive future growth.

Sensus Healthcare reports stellar Q3 performance and eyes global expansion

Sensus Healthcare delivered exceptional Q3 2024 results with doubled revenues, strong profitability, and a robust balance sheet.
The company's strategic strengths include key partnerships, technology diversification, and international market progress.
While challenges like sustaining growth and managing costs exist, Sensus is well-positioned to capitalize on opportunities for expansion and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Sensus Healthcare, Inc. is a medical device company, which engages in the provision of treatment for both oncological and non-oncological skin conditions. The company was founded by Joseph C. Sardano, Richard Golin, Kalman Fishman, and Stephen Cohen on May 7, 2010 and is headquartered in Boca Raton, FL.

Company Management Available for 1x1 Meetings Concurrent with the 40th Annual J.P. Morgan Healthcare Conference January 10-14 Company Management Available for 1x1 Meetings Concurrent with the 40th Annual J.P. Morgan Healthcare Conference January 10-14

Sensus Healthcare to Present at the H.C. Wainwright BioConnect Virtual Conference

AMN Healthcare Services

Ameresco

Vista Outdoor

It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. AMN Healthcare (AMN), Vista Outdoor (VSTO), Sensus Healthcare (SRTS) and Ameresco (AMRC) are well poised to gain.

Fretting Over Market Volatility? Bet on These 4 Low-Beta Stocks

Edwards Lifesciences

Mesa Laboratories

What History Shows Us About 2022 Market Returns

Builders FirstSource

Expeditors International of Washington

Forrester Research

EXPD, FORR, BLDR, and SRTS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on December 17, 2021.

Best Momentum Stocks to Buy for December 17th

Amphastar Pharma

Sanderson Farms

It is imperative to build a portfolio of low-beta stocks to sail through choppy market conditions. Amphastar (AMPH), Sanderson Farms (SAFM) and Sensus Healthcare (SRTS) are well poised to gain.

Sail Through the Choppy Market With These 3 Low-Beta Stocks

Sensus Healthcare, Inc. (SRTS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Sensus Healthcare, Inc. (SRTS) Moves to Strong Buy: Rationale Behind the Upgrade

Dorman Products

Sociedad Quimica Y Minera De Chile

Sensus Healthcare (SRTS), Dorman Products (DORM) & Sociedad Quimica y Minera (SQM) at present flaunt solid earnings acceleration. This calls for investing in them right away.

3 Best Stocks to Invest In for Superb Earnings Acceleration

The average of price targets set by Wall Street analysts indicates a potential upside of 26.8% in Sensus Healthcare, Inc. (SRTS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Believe Sensus Healthcare, Inc. (SRTS) Could Rally 27%: Here's is How to Trade

BuildABear

First Community

Medallion Financial

REX American Resources

We have narrowed our search to five small cap stocks that have surged since the Thanksgiving Day. These are: BBW, FCCO, REX, MFIN and SRTS.

Top 5 Small Caps Flying High Defying Omicron-Led Turmoil

It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Amphastar Pharmaceuticals (AMPH), AMN Healthcare (AMN) & Sensus Healthcare (SRTS) are well poised to gain.

Bet on These 3 Low-Beta Stocks to Combat Market Volatility

The stock price of Sensus Healthcare Inc (NASDAQ: SRTS) increased by 12.21% in the most recent trading session. This is why it happened.

Sensus Healthcare (SRTS) Stock: Why The Price Increased

Sensus to Bring FDA-cleared Non-invasive Drug-delivery System and Treatment Alternative to Needles to Dermatologists Beginning [Immediately/Date] Sensus to Bring FDA-cleared Non-invasive Drug-delivery System and Treatment Alternative to Needles to Dermatologists Beginning [Immediately/Date]

Sensus Healthcare Signs Exclusive U.S. Distribution Agreement with Mattioli Eng. Italia for its TransDermal Infusion System

Dave & Buster's

Dave & Buster's (PLAY), Sensus Healthcare (SRTS) & Sociedad Quimica y Minera (SQM) are worth buying now for superb earnings acceleration.

3 Top-Ranked Stocks to Buy for Solid Earnings Acceleration

Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?

After Golden Cross, Sensus Healthcare, Inc. (SRTS)'s Technical Outlook is Bright

Sensus Healthcare, Inc.'s (SRTS) CEO Joseph Sardano on Q3 2021 Results - Earnings Call Transcript

Sensus Healthcare, Inc. (SRTS) delivered earnings and revenue surprises of 200.00% and 2.70%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Sensus Healthcare, Inc. (SRTS) Tops Q3 Earnings and Revenue Estimates

Achieves profitability on revenues of $5.5 million, up sharply from $1.6 million a year ago

Sensus Healthcare Reports Third Quarter 2021 Financial Results

Sensus Healthcare, Inc. (SRTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Sensus Healthcare, Inc. (SRTS) Report Negative Earnings Next Week? What You Should Know

BOCA RATON, Fla, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, November 4, 2021 at 4:30 p.m. Eastern time to discuss the financial results for the third quarter of 2021. In addition, management will provide a business update and a discussion on recent and upcoming milestones.

Sensus Healthcare to Host Third Quarter 2021 Financial Results and Business Update Conference Call on November 4, 2021

Fireside Chat with CEO Joe Sardano and CFO Javier Rampolla will be held October 19, 2021 at 11:00 a.m. ET Fireside Chat with CEO Joe Sardano and CFO Javier Rampolla will be held October 19, 2021 at 11:00 a.m. ET

Sensus Healthcare to Participate in Fireside Chat Hosted by Maxim Group and M-Vest

Premier gathering expected to host more than 1,200 physicians with 500 virtual participants is the first in-person dermatology medical conference in 18 months

Sensus Healthcare Announces Presentations, Demonstrations and Exhibit Booth at the 2021 Fall Clinical Conference in Las Vegas

Sensus Healthcare, Inc. (SRTS) CEO Joe Sardano on Q2 2021 Results - Earnings Call Transcript

Sensus Healthcare, Inc. (SRTS) delivered earnings and revenue surprises of 60.00% and 33.12%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Sensus Healthcare, Inc. (SRTS) Reports Q2 Loss, Tops Revenue Estimates

Will Sensus Healthcare, Inc. (SRTS) Report Negative Q2 Earnings? What You Should Know

BOCA RATON, Fla, July 29, 2021 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, August 5, 2021 at 4:30 p.m. Eastern time to discuss the financial results for the second quarter of 2021. In addition, management will provide a business update and a discussion on recent and upcoming milestones.

News for Sensus Healthcare Stock (SRTS)